Join to View Full Profile
909 Fulton St SEMinneapolis, MN 55455
Phone+1 612-625-3600
Dr. Desai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Government Medical College, SuratClass of 2013
MedStart Georgetown University HospitalFellowship, Hematology
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine
Certifications & Licensure
MN State Medical License 2020 - 2025
DC State Medical License 2017 - 2020
MI State Medical License 2014 - 2017
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma Start of enrollment: 2024 Dec 04
Roles: Contact
Publications & Presentations
PubMed
- Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic c...Timothy J Voorhees, Eric M McLaughlin, Pallawi Torka, Jorge Florindez, Na Hyun Kim
Blood Cancer Journal. 2025-03-26 - Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.Rahul Lakhotia, Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Sanjal Desai
Leukemia & Lymphoma. 2025-02-03 - 1 citationsCardiovascular Considerations After Cancer Therapy: Gaps in Evidence andExpert Panel Recommendations.Anne Blaes, Anju Nohria, Saro Armenian, Carmen Bergom, Paaladinesh Thavendiranathan
JACC. Cardiooncology. 2025-01-01
Abstracts/Posters
- Prevalence of Chronic Kidney Disease (CKD) in Lymphoma SurvivorsSanjal Desai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell LymphomasSanjal Desai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
